Tocilizumab
Community medical centers can safely administer CAR-T, but extensive preparation required
Chimeric antigen receptor T-cell therapy can be administered at community centers and on an outpatient basis with proper preparation, education and resources, according to prospective study results.
Woman presents with unilateral blurred vision
An 84-year-old woman presented to the Tufts Medical Center emergency department with a chief complaint of blurred vision in the right eye.
Tocilizumab taper increases time to relapse vs. abrupt withdrawal in giant cell arteritis
Tapering tocilizumab leads to a longer relapse-free period in patients with giant cell arteritis, compared with abrupt discontinuation, according to data published in Seminars in Arthritis and Rheumatism.
Kinase Inhibitors
Interleukin-6 Inhibitors
Tocilizumab taper 'reasonable' in giant cell arteritis remission despite flare risk
DESTIN, Fla. — Rheumatologists should consider tapering tocilizumab for patients with giant cell arteritis in remission despite the increased risk for flare, said a speaker at the Congress of Clinical Rheumatology East annual meeting.
FDA approves second tocilizumab biosimilar; first available in IV, subcutaneous forms
The FDA has approved Tyenne, the second tocilizumab biosimilar overall and the first available in both intravenous and subcutaneous formulations, according to a press release from its manufacturer.
VIDEO: ‘Exciting’ approvals for multiple myeloma over the last few years
Celltrion submits application for Actemra biosimilar to FDA
Celltrion USA has submitted a Biologics License Application to the FDA for its tocilizumab biosimilar candidate CT-P47, according to a press release.
US biosimilar market in 2023: Sea change or slow drip?
News pertaining to biosimilars came at a fast and furious pace in 2023.